Objective: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in ®ve well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances. Design: The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone de®ciency (GHD), 29 HIV-infected patients, 25 patients with common variable immunode®ciency (CVI) and 59 age-and sex-matched healthy controls (CTR). Methods: Serum levels of tumor necrosis factor (TNF)-a, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR). Results: OPG levels were signi®cantly elevated in both CVI (median increase ,32%, P , 0X05 and HIV-infected patients with especially high levels in the latter group (,52%, P , 0X001Y signi®cantly correlated with increased TNFa levels r 0X47Y P , 0X02X Also CS patients had elevated serum OPG (,24%, P , 0X01Y signi®cantly correlated with increased serum cortisol r 0X35Y P , 0X05X In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin. Conclusions: These ®ndings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.